Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 26:40:323-348.
doi: 10.1146/annurev-immunol-101220-023458. Epub 2022 Feb 3.

IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19

Affiliations
Review

IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19

Tadamitsu Kishimoto et al. Annu Rev Immunol. .

Abstract

The diverse biological activity of interleukin-6 (IL-6) contributes to the maintenance of homeostasis. Emergent infection or tissue injury induces rapid production of IL-6 and activates host defense through augmentation of acute-phase proteins and immune responses. However, excessive IL-6 production and uncontrolled IL-6 receptor signaling are critical to pathogenesis. Over the years, therapeutic agents targeting IL-6 signaling, such as tocilizumab, a humanized anti-IL-6 receptor antibody, have shown remarkable efficacy for rheumatoid arthritis, Castleman disease, and juvenile idiopathic arthritis, and their efficacy in other diseases is continually being reported. Emerging evidence has demonstrated the benefit of tocilizumab for several types of acute inflammatory diseases, including cytokine storms induced by chimeric antigen receptor T cell therapy and coronavirus disease 2019 (COVID-19). Here, we refocus attention on the biology of IL-6 and summarize the distinct pathological roles of IL-6 signaling in several acute and chronic inflammatory diseases.

Keywords: COVID-19; IL-6R; cytokine storms; interleukin-6; rheumatoid arthritis; tocilizumab.

PubMed Disclaimer

Publication types

LinkOut - more resources